Stocktoria
Theravance Biopharma, Inc. TBPH
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-05-16
Theravance Biopharma, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $107.5M | $64.4M | $57.4M | $51.3M | $55.3M |
| R&D expense | $37.4M | $37.6M | $40.6M | $63.4M | $193.7M |
| SG&A expense | $73.7M | $69.2M | $70.1M | $67.1M | $99.3M |
| Operating income | -$3.6M | -$46.9M | -$56.0M | -$92.0M | -$257.8M |
| Interest expense | — | — | $2.4M | $6.4M | $8.5M |
| Income tax | $23.4M | $11.8M | $5.9M | $9,000 | -$151,000 |
| Net income | $105.9M | -$56.4M | -$55.2M | $872.1M | -$199.4M |
| EPS (diluted) | $2.06 | $-1.15 | $-1.00 | $11.85 | $-2.87 |
| Operating cash flow | $238.5M | -$11.5M | -$27.0M | -$187.0M | -$235.8M |
| Cash & equivalents | $167.8M | $37.8M | $39.5M | $298.2M | $90.0M |
| Total assets | $485.6M | $354.2M | $382.0M | $607.4M | $374.8M |
| Shareholders' equity | $296.7M | $175.5M | $213.0M | $441.8M | -$338.6M |
Source: SEC EDGAR filings · CIK 0001583107 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.